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Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in critically ill patients. Consid-
erable pharmacokinetic (PK) variability is observed in critically ill patients. By estimating an individual’s PK, dosage opti-
mization Bayesian estimation techniques can be used to calculate the appropriate piperacillin regimen to achieve desired
drug exposure targets. The aim of this study was to establish a population PK model for piperacillin in critically ill patients
and then analyze the performance of the model in the dose optimization software program BestDose. Linear, with esti-
mated creatinine clearance and weight as covariates, Michaelis-Menten (MM) and parallel linear/MM structural models
were fitted to the data from 146 critically ill patients with nosocomial infection. Piperacillin concentrations measured in
the first dosing interval, from each of 8 additional individuals, combined with the population model were embedded into
the dose optimization software. The impact of the number of observations was assessed. Precision was assessed by (i) the
predicted piperacillin dosage and by (ii) linear regression of the observed-versus-predicted piperacillin concentrations
from the second 24 h of treatment. We found that a linear clearance model with creatinine clearance and weight as covari-
ates for drug clearance and volume of distribution, respectively, best described the observed data. When there were at least
two observed piperacillin concentrations, the dose optimization software predicted a mean piperacillin dosage of 4.02 g in
the 8 patients administered piperacillin doses of 4.00 g. Linear regression of the observed-versus-predicted piperacillin
concentrations for 8 individuals after 24 h of piperacillin dosing demonstrated an r2 of>0.89. In conclusion, for most crit-
ically ill patients, individualized piperacillin regimens delivering a target serum piperacillin concentration is achievable.
Further validation of the dosage optimization software in a clinical trial is required.
Infection in critically ill patients is associated with excessive mor-bidity,mortality, lengthof hospital stay, andhealth care costs (1, 2).
Early and appropriate antimicrobial therapy is associated with im-
proved clinical outcomes in a variety of clinical contexts (3, 4).Many
licensed antimicrobial regimens are derived fromstudies innon-crit-
ically ill patients, and when they are applied to patients in the inten-
sive care unit (ICU), suboptimal drug exposuremay be the result for
a significant proportion of critically ill patients (5, 6). Marked phar-
macokinetic (PK) variability is characteristic of critically ill patients
and may result from alterations in cardiac output, tissue perfusion,
end-organ dysfunction, increased capillary permeability, hypoalbu-
minemia, and use of extracorporeal circuits. This pharmacokinetic
variability results in a wide range of drug exposures (7). Low drug
exposures increase theprobabilityof clinical failure andemergenceof
antimicrobial resistance, while high drug exposures are associated
with an increased likelihood of toxicity (8).
Piperacillin-tazobactam is widely used to treat infections in
critically ill patients (9). For -lactam agents, the fraction of the
dosing interval that free drug concentrations are above the MIC
(fTMIC) is the pharmacodynamic index that best links drug ex-
posure with the antibacterial effect (10). For piperacillin-tazobac-
tam, the fTMIC of 50% of the dosing interval (50% fTMIC) is
associated with favorable clinical outcomes (8). The use of extended
(or continuous) infusions of -lactam antibiotics increases the
fTMIC and may potentially improve overall efficacy (6, 11). Never-
theless, as many as 20% of patients receiving such regimensmay still
have suboptimal drug exposure (12). The exposure-response rela-
tionships determining emergence of antimicrobial resistance and oc-
currence of adverse events are less well defined. Trough (predose or
minimum concentration of drug in serum [Cmin]) total -lactam
concentrations toMIC ratio of between 3 and 10 have been shown to
prevent the emergence of antimicrobial resistance indynamic in vitro
infectionmodels (13, 14). Piperacillin-tazobactam is usually well tol-
erated, and adverse events are typically detected in2% of patients,
but toxicity has been reported in as many as 50% of patients in
specific cohorts (15). Dosage adjustment of antimicrobial regimens
allows delivery of optimal drug exposures, allowing for variability in
pharmacokinetics, aiming to maximize clinical efficacy, reduce the
chance of adverse events, and suppress the emergence of antimicro-
bial resistance.
Therapeutic drug monitoring (TDM) is a standard of care for
some antimicrobial agents such as gentamicin, vancomycin, and
voriconazole (16–18). Increasing evidence suggests that TDM of
-lactam antibiotics (including piperacillin-tazobactam)may im-
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prove clinical outcomes in critically ill patients (19). Dose adap-
tation using Bayesian approaches offers a potential way of individ-
ualizing regimens for critically ill patients. This approach
estimates a patient’s (Bayesian posterior) pharmacokinetics using
a combination of measured drug concentrations and information
about the drug gained from previous experiences with that drug
(quantified using population pharmacokinetic analysis). Dose-
optimizing software can then identify the optimal dosage to
achieve a predefined target drug concentration.
The aim of this study was to develop a population pharmaco-
kinetic model to describe a large data set of critically ill patients.
The population pharmacokinetic model was incorporated into
the Bayesian dose optimization software program BestDose. We
then assessed the accuracy of the dose optimization software using
in silico validation experiments using multidose pharmacokinetic
data from a small cohort of patients not included in the original
population pharmacokinetic model.
MATERIALS AND METHODS
An overview of the development of the population pharmacokinetic
model and the building, testing, and demonstration of the dosage optimi-
zation software is shown in Fig. 1.
Pharmacokinetic studies of critically ill patients. Pharmacokinetic
data from 146 patients from three previously published studies were ob-
tained (6, 20, 21). A total of 803 piperacillin concentrations were available
with each patient contributing 2 to 10 observations. Patients were admin-
istered between 2 and 4 g of piperacillin by 30-min infusion every 8 h, 4-h
infusion every 8 h, or continuous infusion.
Lodise et al. provided data from 76 patients undergoing abdominal or
thoracic surgery who received 2 g of piperacillin over 30min (20). Plasma
drug concentrations were measured in the first dosing interval. A further
18 patients undergoing colorectal surgery who had received 4 g of pipera-
cillin over 30 min every 6 h were included. Plasma samples were obtained
in the first and second dosing interval.
Plasma drug concentrations from a further 12 hospitalized patients,
who had received 3 g of piperacillin over 4 h every 8 h were included (6).
These patients were predominantly sampled on day 3 of therapy.
Finally, 40 ventilated patients with ventilator-associated pneumonia,
administered piperacillin (12 g or 16 g) by continuous infusion, were
included (21). Plasma samples were collected during the second 24 h of
therapy. Weight and estimated creatinine clearance by Cockcroft-Gault
were known for each patient (22). Piperacillin concentration was mea-
sured, in all three studies, using well-validated high-performance liquid
chromatography assays.
Development of a population pharmacokinetic model of piperacil-
lin. Data were analyzed using a population pharmacokinetic (PK) meth-
odology using the nonparametric adaptive grid program Pmetrics 1.1.1
(23). Since no estimates of uniform assay error were available from the
original studies, we utilized an assay error polynomial where standard
deviation (SD)  1.04  (0.14  C), where C is the drug concentration
(in mg/liter). The polynomial was estimated by linear regression of the
means and associated standard deviation for each of the three piperacillin
concentrations for the 40 patients administered piperacillin by continu-
ous infusion by Boselli et al. (21). In the fitting process, each concentra-
tion was weighted by its Fisher information, which is the inverse of the
variance. Additionally, we chose the option in Pmetrics to multiply the
variance by gamma (	), which is an adaptive scalar that captures addi-
tional process noise such as errors in timing of samples or doses (23).
We evaluated several structural PK models. The details of these struc-
tural models are shown in Fig. 2. The models differed in the way in which
piperacillin was cleared from the central compartment and by the covari-
ates that were included. The models were parameterized in the following
ways: (i) elimination by a first-order process (Fig. 2, equation 1a), (ii)
elimination by a Michaelis-Menten process (Fig. 2, equation 1b), (iii)
elimination by parallel first-order and Michaelis-Menten processes (Fig.
2, equation 1c), and (iv) elimination by a first-order process with creati-
nine clearance as a covariate and body mass as a covariate for the volume
of the central compartment (Fig. 2, equation 1d). Piperacillin elimination,
by a Michaelis-Menten process, is biologically plausible and has previ-
FIG 1 Overview of the development of the population pharmacokinetic model (step 1) and the building (step 2), testing (step 3), and demonstration (step 4) of
the dosage optimization software. Pharmacokinetic data from 146 patients from three previous studies, Felton et al. (6), Boselli et al. (21), and Lodise et al. (20),
were used. The validation cohort of Roberts et al. (27) was used.
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ously been identified to best describe the observed data in a population
pharmacokinetic analysis (6).
For an individual patient without data, i.e., prior to any measured
piperacillin concentrations, his/her parameter value joint distribution is
the same as for the population.However, if observed data are available, the
population distribution (i.e., the Bayesian prior)may be updated to a new
distribution (i.e., the Bayesian posterior) that better predicts the individ-
ual’s observations. The support points do not move, but their relative
probabilities change, based on the ability to predict the patient’s observed
concentrations for his/her dosing history.
For each model, the final-cycle population parameter value distribu-
tions are summarized in terms of measures of central tendency (e.g.,
means and medians) and dispersion (e.g., standard deviation). Scatter-
plots of the observed-versus-predicted values for the population (i.e.,
FIG 2 Structural mathematical models and associated differential equations. X1 and X2 are the amounts of piperacillin (in milligrams) in the central and
peripheral compartments, respectively. R(1) represents the infusion of piperacillin. Cl (in liters per hour) is the clearance, and Vc is the volume of the central
compartment (in liters). Vmax is the maximum rate of clearance by the Michaelis-Menten clearance mechanism (in milligrams per hour), and Km is the
concentration of piperacillin where clearance by the Michaelis-Menten clearance mechanism is half maximal (in milligrams per liter). kcp and kpc are the
first-order intercompartmental rate constants. Cls, fraction of piperacillin clearance due to creatinine clearance (in liters per hour); Cli, clearance due to nonrenal
means (in liters per hour); Vi, volume of the central compartment not related to body mass (in liters); Vs, volume of the central compartment proportional to
body mass (in liters).
Felton et al.
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Bayesian prior) and individual patients (i.e., Bayesian posterior) were
examined. The fit of each of the four structural models to the data was
assessed using a combination of the following: (i) the log likelihood value,
(ii) the Akaike information criterion (AIC), and (iii) the coefficients of
determination (r2) from a linear regression of the observed-predicted
plots before and after the Bayesian step. Differences between the various
models were also assessed statistically by calculating the difference in log
likelihood values and comparing this value to a 
2 distribution with the
degrees of freedom equal to the difference in the number of parameters
between each model.
Building the piperacillin dose optimization software. We used the
dose optimization software programBestDose to estimate each individual
patient’s pharmacokinetics and the optimal individual dosages for each
patient. BestDose is based on software originally developed nearly 20 years
ago by the Laboratory of Applied Pharmacokinetics, University of South-
ern California, Los Angeles (24). This dose optimization software has
previously beenused to individualize therapywith vancomycin, voricona-
zole, and antiretroviral therapy (25, 26).
The BestDose software requires four specific components: (i) a
structural mathematical model that best describes the pharmacokinet-
ics (we used the fourth structural pharmacokinetic model above; see
Results); (ii) the “density” file (one of the outputs of the Pmetrics
analysis), which serves as the Bayesian prior; (iii) a patient “past” file
that contains the observed drug concentrations and details of the ad-
ministered regimen; and (iv) a patient “future” file which contains the
target drug concentrations deemed to be appropriate for that patient
and initial estimates of the required drug dosages and frequency of
administration.
The dose optimization software uses the equations in the model file
and the population Bayesian prior in the density file, together with the
individual patient’s observed drug concentrations in the past data file to
calculate a Bayesian posterior parameter value distribution for that pa-
tient. The dose optimization software then calculates the drug dose that
minimizes the expected weighted squared error (over the Bayesian poste-
rior distribution) between the predicted and user-specified target drug
concentrations in the future data file.
Testing the performance of the piperacillin dosing predictions. A
separate external data set fromRoberts et al. (27) was then used to test the
performance of the piperacillin dose optimization software. Piperacillin
concentrations obtained from eight patients receiving 4 g of piperacillin as
a 20-min infusion every 6 h (n 7) or 8 h (n 1)were used to validate the
performance of the dose optimization software. Patients had amean of 14
observations (range, 12 to 21) during the first dosing interval and a further
9 observations (range, 6 to 12) during a dosing interval 24 h later. The
creatinine clearance was calculated for each patient using the Cockcroft-
Gault equation.
Piperacillin concentrations collected during the first dosing interval
were entered into the dose optimization software. To determine the opti-
mal number of observations required, a comparison was made of one,
two, three, or six observations. Piperacillin concentrations collected ap-
proximately 6 h (1 observation), 0.5 and 6 h (2 observations), 0.5, 3, and 6
h (3 observations), or 0.5, 1, 2, 3, 4, and 6 h (6 observations) after the start
of the first dosage were utilized to describe each individual patient’s phar-
macokinetics. Using 1, 2, or 3 observations was investigated, as these are
reasonable for routine clinical care, while 6 observations is sufficient to
optimally estimate each of the pharmacokinetic parameters in a 6-param-
eter model. Each patient was administered 4 g piperacillin over either 20
or 40 min. The dose optimization software “past” data file contained the
observed first dosing interval piperacillin concentrations for each of the
eight individual validation patients. The “future” data file contained
the required timings of the future dosages, an initial guess at the likely
future dose that would be required to achieve desired concentration
targets (in this case 4 g), the required piperacillin target concentration,
and the timing of the target. For this in silico experiment, the target
piperacillin concentrations at 24.5, 25, 26, 27, 28, and 30 h (6 obser-
vations) after the start of the first dosage were used as the observed
piperacillin values after the first piperacillin dose on the second day of
piperacillin dosing. The output from the dose optimization software
was an estimate of (i) the individual’s (post-Bayesian) pharmacoki-
netic parameters and (ii) the dosage required to achieve the observed
piperacillin concentrations.
The ability of thedoseoptimization softwarewas tested in twoways. First,
the capability of the software to estimate each individual’s pharmacokinetics
was assessed by comparison of the observed-versus-predicted piperacillin
concentration after 24 h of therapy. Simulations, utilizing parameter esti-
mates from each of the eight validation individuals, was performed using
ADAPT 5 (28). The piperacillin concentrations at the corresponding time
points to the observed data during the second 24 h of treatment were esti-
mated. The ability of the dose optimization software to predict the observed
data was evaluated by the following: (i) visual inspection of the simulated
piperacillin concentration-time profiles for the eight individual patients, in-
cluding the observed piperacillin concentrations; (ii) linear regression of the
observed-versus-predicted piperacillin concentrations for each of the eight
validation individuals; and (iii) linear regression and estimation of the mean
weighted prediction error (bias) and the bias-adjusted squared prediction
error (precision) of the observed-versus-predicted piperacillin concentra-
tions for all eight patients combined.
Second, the dose optimization software was tested by comparing the
estimated delivered piperacillin dosage predicted from the observed pip-
eracillin concentrations after 24 h of therapy. Assessment was made by
comparison of actual and predicted piperacillin dosages after 24 h of treat-
ment.
TABLE 1 Demographics and clinical characteristics of the 146 patients used in this study
Demographic or
clinical
characteristic
Mean (median) [range] value for the characteristic in the following studya:
Felton et al. Boselli et al. Lodise et al. Combined Roberts et al.
Estimated creatinine
clearance
(ml/min)
115.0 (111.5) [38.0–169.1] 69.8 (52.0) [14.0–245.7] 89.0 (85.5) [27.0–221.0] 85.9 (81.0) [14.0–245.7] 165.5 (163.7) [58.8–256.6]
Wt (kg) 77.0 (71.5) [38.1–122.5] 73.0 (68.5) [49.0–113.0] 70.5 (69.0) [50.0–98.5] 71.7 (69.0) [38.1–122.5] 86.8 (82.5) [72.0–132.0]
Sex (no. of males:
no. of females)
8:4 25:15 54:40 87:59 6:2
Age (yr) 46.8 (49.5) [20.0–69.0] 62.3 (64.0) [34.0–88.0] 54.2 (55.0) [18.0–78.0] 55.8 (56.0) [18.0–88.0] 43.6 (41) [19.0–75.0]
No. of patients 12 40 94 146 8
No. of doses 9.58 (9.00) [4.00–24.00] 48-h continuous infusion 1 or 2 N/A 4 or 5
No. of observations
per patient
5.9 (6.0) [4.0–8.0] 3.0 (3.0) [3.0–3.0] 6.5 (6.0) [2.0–10.0] 5.5 (6.0) [2.0–10.0] 24 (24) [21–26]
a The values for three studies, Felton et al. (6), Boselli et al. (21), and Lodise et al. (20), are shown. The values for the three studies together are shown in the Combined column. The
values for the validation cohort of Roberts et al. (27) are shown. N/A, not available.
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Linear regression was performed using GraphPad Prism version 5 for
Windows (GraphPad Software, San Diego, CA, USA). Estimation of the
mean weighted prediction error and the bias-adjusted squared prediction
error was performed in R 3.0.1 (29).
Simulations to demonstrate the utility of the dose optimization
software. The dose optimization software was finally used to predict the
required dosage to achieve a predetermined piperacillin concentration. In
this analysis, the same six time points, from the first 24 h of piperacillin
therapy administered to the eight validation patients, were used. For each
of the eight individuals, three doses of drug were administered in the first
24 h at 8-h intervals. This was to simulate the time required tomeasure the
drug concentration after the first dose. Dosage adjustment was then per-
formed for the fourth to seventh doses because day 2 of treatment repre-
sents an early opportunity for TDM intervention. The piperacillin target
concentration was a predose (trough) concentration estimated from an in
vitro hollow-fiber infection model, containing Pseudomonas aeruginosa.
The identified concentration is associated with suppression of emergence
of piperacillin resistance (30). The target trough total plasma piperacillin
concentrations used were 13.6 mg/liter and 41.6 mg/liter for 30-min and
4-h infusion regimens, respectively. These concentrations would be ap-
plicable to a strain of Pseudomonas aeruginosawith a MIC of 4 mg/liter as
used in the in vitromodel.
RESULTS
Population pharmacokinetics of piperacillin in critically ill pa-
tients. The demographics and clinical characteristics of the 146
patients used in this study are summarized in Table 1. A com-
parison of the fit of each of the four structural mathematical
models to the data is shown in Table 2. All four models per-
formed well. Evaluation of the log likelihood values against a 
2
distribution and comparison of Akaike information criterion
indicated that the Michaelis-Menten model was superior to the
other mathematical models. Examination of the linear regres-
sion of the observed-versus-predicted plots revealed that each
model showed an r2 of 0.9, but the linear clearance model
with covariates had a y-intercept value closest to zero. As all the
models perform similarly, the linear clearance model with co-
variates, the most clinically relevant model, was used to predict
the pharmacokinetics of critically ill individual patients and
their optimal piperacillin dosage despite being statistically in-
ferior to the Michaelis-Menten model. The mean, median, and
standard deviation of the parameter estimates for the linear
clearance with covariates population pharmacokinetic model
are shown in Table 3.
Predicting pharmacokinetics of individual critically ill pa-
tients. Linear regression of the data for individual patients re-
vealed r2 values ranging from 0.861 to 0.987 using a single obser-
vation, 0.893 to 0.987 using two observations, 0.883 to 0.979 for
three observations, and 0.833 to 0.967 for six observations (Table 4).
Linear regression of the combined observed-predicted values,
from all eight individuals, revealed r2 values of 0.727 using a single
observation, 0.805 using two observations, 0.738 using three ob-
servations, and 0.681 using six observations (Fig. 3). The mean
weighted prediction error (bias) and bias-adjusted squared pre-
diction error (precision) were 3.66mg/liter and 184.26mg2/liter2,
respectively, using a single observation, 4.73 mg/liter and 130.32
mg2/liter2, respectively, using two observations, 2.32 mg/liter and
91.45 mg2/liter2 mg/liter, respectively, using three observations,
and 1.01 and 117.32 mg2/liter2, respectively, using six observa-
tions. Visual inspection of the concentration-time profiles for
each of the eight patients showed predicted concentrations were
higher than the observed concentration following a single obser-
vation. For seven of the eight validation patients, utilizing more
than one observation resulted in a satisfactory agreement between
the observed piperacillin concentration at 24 h and the piperacil-
lin concentration predicted by the population pharmacokinetic
model (Fig. 4). For patient 3, the model did not predict the ob-
served data well, but inspection of the raw data showed consider-
able differences between the observed piperacillin concentrations
resulting from the first and fifth dosage.
Predicting the piperacillin dosage delivered to individual
critically patients. From a single postdose observation, collected
following 24 h of therapy, themean andmedian predicted pipera-
cillin doses for the cohort of eight validation patients were 3.58
and 2.86 g, respectively, compared with a delivered dose of 4.00 g
(Table 4 and Fig. 5). For two postdose observations, themean and
median predicted piperacillin doses were 4.02 and 3.47 g, respec-
tively, compared tomean andmedian predicted piperacillin doses
of 4.55 and 3.65 g following three observations and 5.52 and 4.20
g if six observations were used. When at least two observed pip-
eracillin concentrationswere used, the dose optimization software
predicted that patient 3 required at least twice the administered
dose of piperacillin to achieve the observed piperacillin concen-
trations. For this patient, inspection of the observed piperacillin
TABLE 2 Evaluation of the predictive performance of piperacillin and tazobactam population models
Model
No. of
variables Log likelihood

2 compared to
linear model
No. of cycles to
convergence AIC
Linear regression of observed-
predicted values for each patient
R2 Intercept Slope
Linear 4 2,973.5 N/A 1,310 2,988 0.931 2.43 0.903
Michaelis-Menten 5 2,892.5 2.26E19 1,490 2,914 0.933 3.35 0.921
Parallel linear/MM 6 2,894.5 7.00E18 2,182 2,922 0.933 3.42 0.908
Linear with
covariatesa
6 2,899.0 6.65E17 1,061 2,930 0.925 2.27 0.918
a The model selected for the dose optimization software validation.
TABLE 3 Data on the parameter estimates for the linear clearance with
covariates population pharmacokinetic model
Parametera Mean [median] SD
Cli 3.83 [2.79] 3.35
Cls 0.11 [0.10] 0.07
Vi 4.54 [1.83] 4.43
Vs 0.12 [0.06] 0.12
kcp 6.74 [0.85] 11.38
kpc 9.14 [1.65] 13.13
a Parameters defined in the legend to Fig. 2.
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concentrations (Fig. 4) shows that the piperacillin concentrations
after 24 h of therapy are markedly higher than the piperacillin
concentrations achieved after the first dose, but with little sign of
significant drug accumulation.
Examples of the clinical utility of the piperacillin dose opti-
mization software. The dose optimization software was used, in
silico, to predict a specified trough piperacillin concentration fol-
lowing a 30-min administration of piperacillin every 8 h. In order
TABLE 4 Linear regression of data for individual patients with different numbers of observations
Patient
1 observation 2 observations 3 observations 6 observations
r2
Predicted piperacillin
dose (g) [% of
delivered dose] r2
Predicted piperacillin
dose (g) [% of
delivered dose] r2
Predicted piperacillin
dose (g) [% of
delivered dose] r2
Predicted piperacillin
dose (g) [% of
delivered dose]
1 0.861 2.68 [33.0] 0.918 5.22 [30.5] 0.972 4.87 [21.7] 0.940 4.97 [24.3]
2 0.928 1.76 [55.9] 0.947 1.15 [71.3] 0.897 1.71 [57.2] 0.897 1.67 [58.2]
3 0.976 9.49 [137.3] 0.981 8.72 [118.1] 0.883 11.64 [191.0] 0.959 17.65 [341.2]
4 0.925 3.10 [22.4] 0.919 3.05 [23.9] 0.890 3.53 [11.8] 0.833 3.42 [14.5]
5 0.987 4.81 [20.3] 0.987 4.33 [8.3] 0.979 5.05 [26.1] 0.892 5.62 [40.5]
6 0.963 3.04 [23.9] 0.920 3.83 [4.3] 0.970 3.76 [5.9] 0.938 5.05 [26.2]
7 0.967 1.85 [53.8] 0.959 3.10 [22.4] 0.960 3.32 [17.0] 0.967 3.08 [23.0]
8 0.905 1.89 [52.6] 0.893 2.76 [31.0] 0.893 2.54 [36.4] 0.859 2.71 [32.3]
Mean 3.58 [10.5] 4.02 [0.5] 4.55 [13.8] 5.52 [38.0]
Median 2.86 [28.5] 3.47 [13.4] 3.65 [8.8] 4.20 [4.9]
FIG 3 Observed-versus-predicted piperacillin concentrations for the in silico validation cohort using 1, 2, 3, or 6 measurements to determine the predicted
postdose piperacillin concentrations after 24 h of therapy. The data points (), linear regression (solid line), and unity (gray dashed line) are shown (bias is the
mean weighted prediction error [mg/liter]; precision is the bias-adjusted squared prediction error [mg2/liter2]).
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to achieve the target piperacillin concentration, piperacillin 4.7 g
and 8.8 g, administered every 8 h by 30-min infusion, were re-
quired for patients 1 and 8, respectively (Fig. 6).
DISCUSSION
Infection remains a commonly encountered problem in critically
ill patients and is associated with high morbidity, high mortality,
and increased health care costs. Variation in the pharmacokinetics
of-lactam antibiotics occurs in critically ill patients (31). The use
of a fixed regimen in critically ill patients will result in a wide
range of drug exposures (32). Therapeutic drug monitoring
(TDM) enables adjustment of the dose based on observed drug
concentrations to achieve optimal drug exposure for an individual
patient. TDM is a standard of care for some agents, such as gen-
tamicin, vancomycin, and voriconazole, and is associated with
improved clinical outcomes (16, 17). There is limited evidence
suggesting that TDM improves achievement of pharmacody-
namic targets for -lactam antibiotics (19, 33).
Here, we develop and validate the necessary tools to enable
dosage individualizuation of piperacillin in critically ill pa-
tients. Administration of -lactams by extended or continuous
infusion or through application of TDM has been suggested to
exploit relatively detailed understanding of -lactam pharma-
codynamics. Continuous infusions have been shown to achieve
the desired pharmacodynamic target in only ca. 80% of criti-
cally ill patients (12). This could, potentially, be improved us-
ing TDM and dose optimization. Typically, TDM is performed
using dosing nomograms. However, the use of dosing nomo-
grams in critically ill patients poorly predicts the required drug
regimen (34, 35). This is due to the considerable pharmacoki-
netic variability in study populations. Additionally, dosing no-
mograms require assessment of a subject with the drug at phar-
macokinetic steady state, whereas Bayesian dose optimization
may be performed after the first dose. Finally, Bayesian dose
optimization offers a truly personalized dosage for each patient
rather than forcing the individual into one of several potential
dosing bands. A pragmatic interpretation of the dosage identi-
fied by the dosing software may be required, so a practical and
easy-to-administer dose could be prescribed to the patient.
This dosage would result in a drug concentration that safely
exceeds the identified plasma therapeutic target.
Both inter- and intrasubject pharmacokinetic variability may
be important. Intersubject variability is fundamental to the argu-
ment for usingTDM—i.e., inherent variability results in toomany
patients receiving suboptimal drug exposures. Intrasubject vari-
ability (due to the continually changing clinical state and pharma-
cokinetics observed in critically ill patients) has an impact on the
ability to accurately predict a regimen that enables attainment of a
desired therapeutic target in an optimally precise manner. This is
illustrated by patient 3 in Fig. 4. Visual inspection of the concen-
tration-time profiles (Fig. 4) illustrates the difference between the
observed and predicted piperacillin concentrations after 24 h of
therapy. This was due to a marked and rapid change in both pip-
eracillin clearance and volumeof distribution.Use of amathemat-
ical nonlinear clearance model may have estimated the accumu-
lation of piperacillin seen in patient 3. Additionally, optimal
FIG 4 Piperacillin concentration-time profiles for eight validation patients generated from six observed piperacillin concentrations during the first dosing
interval. Observed data entered into the software package () and observed data unknown to the software package (Œ) are shown. The predicted piperacillin
concentration-time profiles are indicated by the solid lines.
FIG 5 Comparison of the impact of entering one, two, three, or six known
first-dose piperacillin concentrations into the dose optimization software on
predicted piperacillin dosage for patients actually administered piperacillin (4
g). Each symbol represents the value for an individual patient, and the black
lines represent the mean values for the groups of patients.
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design of plasma sampling time points may maximize the infor-
mation gained from each sample and allow better estimation of
parameters, such as clearance and volume of distribution. It is
likely that repeated assessment of a patient’s observed drug con-
centration will be required, especially in patients with discernible
changes in their clinical condition.
The change in pharmacokinetic parameters results from patho-
physiological changes in critically ill patients. In order for a mathe-
matical model to predict a patient’s pharmacokinetic changes, a
greater understanding of pathophysiological alterations is required.
Quantification of these pathophysiological changes and subsequent
incorporation as covariates into a mathematical model may allow
better prediction of evolving pharmacokinetics and requires further
study. Alternatively, a more pragmatic approach would be frequent
observation and dosage adjustment performed with a minimum of
delaybetweenobservation andadjustment. In this in silico validation,
the time between the two sets of observations was 24 h. This is a
reasonable estimate for the current amount of time it would take to
process,measure, and thenmodel theobserveddatabeforebeingable
to change the regimen. Reducing the turnaround time would mean
less time for pathophysiological alterations to change the dosing re-
quirements. In unstable, critically ill patients, the process of measur-
ing drug concentrations and establishing the optimal antimicrobial
regimenmay be a nearly continuous process. Reformatting drug as-
says to platforms, such as enzyme immunoassay, and away from
chromatographymay reduce time delays in producing drug concen-
tration data. Additionally, moving the equipment required for TDM
closer to the patient will minimize the turnaround time (36, 37). In
the future,weanticipate thatdrugquantificationwill beperformed in
a similar way to glucose measurement using handheld devices at the
bedside with built-in dosing software.
The drug exposure target used for dosage adjustment in the in
silico validation experiment was identified in an in vitro dynamic
pharmacokinetic/pharmacodynamic experiment (14). Here a strain
of Pseudomonas aeruginosa with a MIC of 4 mg/liter was exposed
to a range of piperacillin-tazobactam dosages. The identified tar-
get piperacillin concentration, expressed as a product of the MIC,
was the lowest predose concentration required to suppress the
emergence of piperacillin resistance. Two different TDM target
concentrations were identified, both for piperacillin administered
every 8 h, one by 30-min bolus injection and a separate target for
4-h extended infusions. To achieve this trough concentration,
piperacillin dosages markedly higher than currently licensed may
be required. This is illustrated by patient 8, who was predicted to
require 7.4 g or 11.8 g of piperacillin, depending on the regimen,
to achieve the target concentration. Use of these high piperacillin
dosages would require attention to patient safety, although the
resulting concentrations appear to be well tolerated (19).
The results of this in silico validation experiment illustrate the
complexities of optimizing treatment for critically ill patients. The
dose optimization software allows precise targeting of drug con-
centrations as previously demonstrated with voriconazole (38).
The changing pathophysiology of critically ill patients and vari-
ability in pharmacokinetics makes delivery of optimized regimens
challenging. Despite these challenges, the dose optimization soft-
ware, when at least two observed concentrations were used, was
able to provide a satisfactory response in seven of the eight pa-
tients. Rapid, near-patient drug quantification would reduce the
impact of pharmacokinetic variability and may be required to
further personalize and optimize antimicrobial therapies in the
ICU. The ability of TDM and Bayesian dose adaptation of -lac-
tam antibiotics to improve outcomes in critically ill patients re-
quires evaluation in prospective randomized studies.
ACKNOWLEDGMENTS
T. W. Felton is an MRC Clinical Training Fellow supported by the North
WestEnglandMedicalResearchCouncil FellowshipScheme inClinicalPhar-
macology andTherapeutics, which is funded by theMedical ResearchCoun-
cil (grant G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the
Medical Evaluation Unit. J. A. Roberts is funded by a Career Development
Fellowship from the National Health andMedical Research Council of Aus-
tralia (APP1048652). W. W. Hope is supported by a Clinician Scientist Fel-
lowship from the National Institute of Health Research.
REFERENCES
1. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H,
Moreno R, Carlet J, Le Gall J-R, Payen D. 2006. Sepsis in European
intensive care units: results of the SOAP study. Crit. Care Med. 34:344–
353. http://dx.doi.org/10.1097/01.CCM.0000194725.48928.3A.
2. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of
sepsis in the United States from 1979 through 2000. N. Engl. J. Med.
348:1546–1554. http://dx.doi.org/10.1056/NEJMoa022139.
3. Kollef MH. 1999. Inadequate antimicrobial treatment of infections: a risk
factor for hospital mortality among critically ill patients. Chest 115:462–
474. http://dx.doi.org/10.1378/chest.115.2.462.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R,
Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006.
Durationof hypotensionbefore initiationof effective antimicrobial therapy is
FIG 6 Predicted piperacillin concentration-time profiles for patients 1 and 8. The observed data entered into the software package () and the predicted
piperacillin concentration (solid line) are shown. At the top of each graph, each arrowhead represents an administered dose (doses administered prior to
individualization [all bolus doses] [] and doses administered following individualization [administration over 30 min for bolus doses] [p]). The therapeutic
drug target was a trough piperacillin concentration of 13.6 mg/liter.
Piperacillin Dose Optimization
July 2014 Volume 58 Number 7 aac.asm.org 4101
 o
n
 N
ovem
ber 5, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
the critical determinant of survival in human septic shock. Crit. Care Med.
34:1589–1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
5. Roberts JA, Lipman J. 2006. Antibacterial dosing in intensive care: pharma-
cokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharma-
cokinet. 45:755–773. http://dx.doi.org/10.2165/00003088-200645080-00001.
6. Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL,
Drusano GL, Lodise TP. 2012. Population pharmacokinetics of extend-
ed-infusion piperacillin-tazobactam in hospitalized patients with nosoco-
mial infections. Antimicrob. Agents Chemother. 56:4087–4094. http://dx
.doi.org/10.1128/AAC.00521-12.
7. Patel N, Scheetz MH, Drusano GL, Lodise TP. 2010. Identification of
optimal renal dosage adjustments for traditional and extended-infusion
piperacillin-tazobactamdosing regimens in hospitalized patients. Antimi-
crob. Agents Chemother. 54:460–465. http://dx.doi.org/10.1128/AAC
.00296-09.
8. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interac-
tions of ‘bug and drug’. Nat. Rev. Microbiol. 2:289–300. http://dx.doi.org
/10.1038/nrmicro862.
9. Rello J, Ulldemolins M, Lisboa T, Koulenti D, Mañez R, Martin-
Loeches I, De Waele JJ, Putensen C, Guven M, Deja M, Diaz E,
EU-VAP/CAP Study Group. 2011. Determinants of prescription and
choice of empirical therapy for hospital-acquired and ventilator-
associated pneumonia. Eur. Respir. J. 37:1332–1339. http://dx.doi.org/10
.1183/09031936.00093010.
10. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: ratio-
nale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1–10.
http://dx.doi.org/10.1086/516284.
11. Lodise TP, Lomaestro BM, Drusano GL. 2007. Piperacillin-tazobactam
for Pseudomonas aeruginosa infection: clinical implications of an extend-
ed-infusion dosing strategy. Clin. Infect. Dis. 44:357–363. http://dx.doi
.org/10.1086/510590.
12. Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall
C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J.
2013. Continuous infusion of beta-lactam antibiotics in severe sepsis: a
multicenter double-blind, randomized controlled trial. Clin. Infect. Dis.
56:236–244. http://dx.doi.org/10.1093/cid/cis856.
13. Tam VH, Schilling A, Neshat S. 2005. Optimization of meropenem
minimum concentration/MIC ratio to suppress in vitro resistance of
Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920–
4927. http://dx.doi.org/10.1128/AAC.49.12.4920-4927.2005.
14. Felton TW, Goodwin J, O’Connor L, Sharp A, Gregson L, Livermore J,
Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus
continuous infusion of piperacillin and tazobactam on the development of
antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob. Agents
Chemother. 57:5811–5819. http://dx.doi.org/10.1128/AAC.00867-13.
15. Hayashi Y, Roberts JA, Paterson DL, Lipman J. 2010. Pharmacokinetic
evaluation of piperacillin-tazobactam. ExpertOpin. DrugMetab. Toxicol.
6:1017–1031. http://dx.doi.org/10.1517/17425255.2010.506187.
16. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008.
Voriconazole therapeutic drug monitoring in patients with invasive my-
coses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201–211.
http://dx.doi.org/10.1086/524669.
17. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA.
1999. Impact of goal-oriented and model-based clinical pharmacokinetic
dosing of aminoglycosides on clinical outcome: a cost-effectiveness anal-
ysis. Ther. Drug Monit. 21:63–73. http://dx.doi.org/10.1097/00007691
-199902000-00010.
18. International Association of Therapeutic Drug Monitoring and Clinical
Toxicology. 2011. Definition of TDM. International Association of Thera-
peuticDrugMonitoringandClinicalToxicology,Kingston,Ontario,Canada.
http://www.iatdmct.org/about-us/about-association/about-definitions-tdm
-ct.html.
19. Roberts JA, Ulldemolins M, Roberts MS, McWhinney BC, Ungerer J,
Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of beta-
lactams in critically ill patients: proof of concept. Int. J. Antimicrob.
Agents 36:332–339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.
20. Lodise TP, Lomaestro BM, Rodvold KA, Danziger LH, Drusano GL.
2004. Pharmacodynamic profiling of piperacillin in the presence of tazo-
bactam in patients through the use of population pharmacokineticmodels
and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718–
4724. http://dx.doi.org/10.1128/AAC.48.12.4718-4724.2004.
21. Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux M-C,
Bouvet L, Chassard D, Allaouchiche B. 2008. Alveolar concentrations of
piperacillin/tazobactam administered in continuous infusion to patients
with ventilator-associated pneumonia. Crit. Care Med. 36:1500–1506.
http://dx.doi.org/10.1097/CCM.0b013e318170ba21.
22. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from
serum creatinine. Nephron 16:31–41. http://dx.doi.org/10.1159/000180580.
23. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW.
2012. Accurate detection of outliers and subpopulations with Pmetrics, a
nonparametric and parametric pharmacometric modeling and simula-
tion package for R. Ther. Drug Monit. 34:467–476. http://dx.doi.org/10
.1097/FTD.0b013e31825c4ba6.
24. Jelliffe RW, Bayard D, Schumitzky A, Milman M, Van Guilder M. 1995.
Pharmaco-informatics:more precise drug therapy from “multiplemodel”
(MM) adaptive control regimens: evaluation with simulated vancomycin
therapy. Medinfo 8(Part 2):1106–1110.
25. Neely MN, Rakhmanina NY. 2011. Pharmacokinetic optimization of
antiretroviral therapy in children and adolescents. Clin. Pharmacokinet.
50:143–189. http://dx.doi.org/10.2165/11539260-000000000-00000.
26. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC.
2011. Vancomycin dosing: assessment of time to therapeutic concentra-
tion and predictive accuracy of pharmacokinetic modeling software. Ann.
Pharmacother. 45:757–763. http://dx.doi.org/10.1345/aph.1P634.
27. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. 2010.
First-dose and steady-state population pharmacokinetics and pharmaco-
dynamics of piperacillin by continuous or intermittent dosing in critically
ill patients with sepsis. Int. J. Antimicrob. Agents 35:156–163. http://dx
.doi.org/10.1016/j.ijantimicag.2009.10.008.
28. D’Argenio DZ, Schumitzky A, XiaoningW. 2009. ADAPT 5 user’s guide:
pharmacokinetic/pharmacodynamic systems analysis software. Biomedi-
cal Simulations Resource, Los Angeles, CA.
29. The R development core team. 2013. R: a language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna,
Austria.
30. Felton TW, Goodwin J, O’Connor L, Sharp A, Gregson L, Livermore J,
Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus
continuous infusion of piperacillin and tazobactam on the development of
antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob. Agents
Chemother. 57:5811–5819. http://dx.doi.org/10.1128/AAC.00867-13.
31. Roberts JA, Norris R, Paterson DL, Martin JH. 2012. Therapeutic drug
monitoring of antimicrobials. Br. J. Clin. Pharmacol. 73:27–36. http://dx
.doi.org/10.1111/j.1365-2125.2011.04080.x.
32. Roberts JA, Hope WW, Lipman J. 2010. Therapeutic drug monitoring of
beta-lactams for critically ill patients: unwarranted or essential? Int. J.
Antimicrob. Agents 35:419–420. http://dx.doi.org/10.1016/j.ijantimicag
.2010.01.022.
33. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe
SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. 2012. Therapeu-
tic drug monitoring of beta-lactam antibiotics in burns patients–a one-
year prospective study. Ther. Drug Monit. 34:160–164. http://dx.doi.org
/10.1097/FTD.0b013e31824981a6.
34. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. 2002.
Experience with a once-daily dosing program of aminoglycosides in crit-
ically ill patients. Intensive Care Med. 28:936–942. http://dx.doi.org/10
.1007/s00134-002-1313-7.
35. Pea F, Viale P, Cojutti P, Furlanut M. 2012. Dosing nomograms for
attaining optimum concentrations ofmeropenemby continuous infusion
in critically ill patients with severe Gram-negative infections: a pharmaco-
kinetics/pharmacodynamics-based approach. Antimicrob. Agents Che-
mother. 56:6343–6348. http://dx.doi.org/10.1128/AAC.01291-12.
36. Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete
AG. 2012. Quantification of seven -lactam antibiotics and two -lactamase
inhibitors in human plasma using a validated UPLC-MS/MSmethod. Int. J.
Antimicrob. Agents 40:416–422. http://dx.doi.org/10.1016/j.ijantimicag
.2012.06.022.
37. Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JPJ. 2012. A
method fordetermining the free (unbound) concentrationof tenbeta-lactam
antibiotics in humanplasmausing high performance liquid chromatography
withultravioletdetection. J.Chromatogr.BAnalyt.Technol.Biomed.LifeSci.
907:178–184. http://dx.doi.org/10.1016/j.jchromb.2012.09.016.
38. Hope WW, Vanguilder M, Donnelly JP, Blijlevens NMA, Brüggemann
RJM, Jelliffe RW, Neely MN. 2013. Software for dosage individualization
of voriconazole for immunocompromised patients. Antimicrob. Agents
Chemother. 57:1888–1894. http://dx.doi.org/10.1128/AAC.02025-12.
Felton et al.
4102 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 N
ovem
ber 5, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
